Facet Biotech Announces Daclizumab Program in Multiple Sclerosis to Advance Company Plans to Request Special Protocol Assessment for Phase 3 Trial REDWOOD CITY, CA, Aug 03, 2009 -- Facet Biotech ...
FACETS began its annual Hypothermia Prevention and Response Program in late November and has experienced an increase in demand with cold weather and local need pushing up the numbers of people seeking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results